The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | Improving patient communication in CLL
Zack Pemberton-Whiteley, Leukemia Care, Worcester, UK, discusses how information provision affects the experience of patients with chronic lymphocytic leukemia (CLL). Mr Pemberton-Whiteley discusses the findings of the “Living With Leukemia” survey, which reported that information regarding watch-and-wait treatment strategies was insufficiently communicated to patients and resulted in poorer experiences. The survey found that a lack of information was associated with a significantly greater likelihood of worry; however, poorly explained information produced patients outcomes which were worse than for patients who were given no information. This highlights the importance of clear communication. Mr Pemberton-Whiteley also talks on the role clinical nurse specialists (CNSs) constitute as an important source of information, having a positive impact on patients experience. Despite this, only 56% of patients with CLL in the UK have access to CNSs, which dropped to 29% for those on watch-and-wait. Improving CNS accessibility may improve information provision and thus overall patient experience. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
Disclosures
Zack Pemberton-Whiteley is the CEO of Leukemia Care, UK, the Chair of the Acute Leukemia Advocates Network (ALAN), and has received institutional grant funding and/or honoraria from AbbVie, Agios, Amgen, Astellas, Autolus, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Incyte, Jazz, Janssen, Kite, Kyowa Kirin, Mallinckrodt, Novartis, Pfizer, Roche, Servier and Takeda.
